IL263245B - A method for treating liver cirrhosis - Google Patents

A method for treating liver cirrhosis

Info

Publication number
IL263245B
IL263245B IL263245A IL26324518A IL263245B IL 263245 B IL263245 B IL 263245B IL 263245 A IL263245 A IL 263245A IL 26324518 A IL26324518 A IL 26324518A IL 263245 B IL263245 B IL 263245B
Authority
IL
Israel
Prior art keywords
liver fibrosis
treating liver
treating
fibrosis
liver
Prior art date
Application number
IL263245A
Other languages
English (en)
Hebrew (he)
Other versions
IL263245A (en
Original Assignee
Chemocentryx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemocentryx Inc filed Critical Chemocentryx Inc
Publication of IL263245A publication Critical patent/IL263245A/en
Publication of IL263245B publication Critical patent/IL263245B/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/18Sulfonamides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
IL263245A 2016-06-03 2018-11-25 A method for treating liver cirrhosis IL263245B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662345086P 2016-06-03 2016-06-03
PCT/US2017/035628 WO2017210526A1 (en) 2016-06-03 2017-06-02 Method of treating liver fibrosis

Publications (2)

Publication Number Publication Date
IL263245A IL263245A (en) 2018-12-31
IL263245B true IL263245B (en) 2021-09-30

Family

ID=60479090

Family Applications (1)

Application Number Title Priority Date Filing Date
IL263245A IL263245B (en) 2016-06-03 2018-11-25 A method for treating liver cirrhosis

Country Status (15)

Country Link
US (3) US10682344B2 (https=)
EP (1) EP3463350B1 (https=)
JP (2) JP2019517523A (https=)
KR (1) KR102444366B1 (https=)
CN (2) CN115154467B (https=)
AU (1) AU2017274521B2 (https=)
BR (1) BR112018074452A2 (https=)
CA (1) CA3025671C (https=)
ES (1) ES2966111T3 (https=)
IL (1) IL263245B (https=)
MX (1) MX387070B (https=)
RU (1) RU2740902C2 (https=)
SG (2) SG11201810602YA (https=)
WO (1) WO2017210526A1 (https=)
ZA (1) ZA201807992B (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2545964A1 (en) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
US11571431B2 (en) 2013-12-04 2023-02-07 Galmed Research And Development Ltd Aramchol salts
IL243707A0 (en) 2016-01-20 2016-05-01 Galmed Res And Dev Ltd Treatment to regulate the microbiota in the intestine
SG11201810602YA (en) * 2016-06-03 2018-12-28 Chemocentryx Inc Method of treating liver fibrosis
MX385718B (es) 2016-06-13 2025-03-18 Gilead Sciences Inc Compuestos moduladores de fxr (nr1h4).
CA3252823A1 (en) 2016-06-13 2025-02-25 Gilead Sciences, Inc. Substituted tert-butyl-3-(2-chloro-phenyl)-3-hydroxyazetidine-1-carboxylate compounds
US11197870B2 (en) 2016-11-10 2021-12-14 Galmed Research And Development Ltd Treatment for hepatic fibrosis
IL311409A (en) * 2016-11-10 2024-05-01 Galmed Res And Development Ltd Use of Amcol for the treatment of fibrosis
PT3600309T (pt) 2017-03-28 2022-10-03 Gilead Sciences Inc Combinações terapêuticas para o tratamento de doenças hepáticas
US11707472B2 (en) 2017-06-05 2023-07-25 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis
US11542256B2 (en) 2017-09-03 2023-01-03 Angion Biomedica Corp. Vinylheterocycles as Rho-associated coiled-coil kinase (ROCK) inhibitors
WO2019149089A1 (zh) 2018-02-02 2019-08-08 四川科伦博泰生物医药股份有限公司 含有羧酸基团的苯并氮杂环类化合物及其制备方法和用途
ES3053674T3 (en) 2018-03-22 2026-01-23 Viking Therapeutics Inc Crystalline forms and methods of producing crystalline forms of a compound
CN111801324B (zh) * 2018-06-12 2021-10-22 四川海思科制药有限公司 甲状腺激素受体激动剂及其用途
US20210322324A1 (en) * 2018-08-14 2021-10-21 Avolynt Method for treating primary sclerosing cholangitis
GB201813678D0 (en) * 2018-08-22 2018-10-03 Keybioscience Ag Acylated calcitonin mimetics
WO2020117962A1 (en) 2018-12-05 2020-06-11 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis and inflammation
EP3911647B1 (en) 2019-01-15 2023-12-13 Gilead Sciences, Inc. Isoxazole compound as fxr agonist and pharmaceutical compositions comprising same
CA3233305A1 (en) 2019-02-19 2020-08-27 Gilead Sciences, Inc. Solid forms of fxr agonists
WO2020181163A1 (en) * 2019-03-06 2020-09-10 Tobira Therapeutics, Inc. Lipid-based formulation of cenicriviroc
GEP20247637B (en) 2019-05-08 2024-06-25 Aligos Therapeutics Inc Modulators of thr-b and methods of use thereof
EP4006552A2 (en) * 2019-07-30 2022-06-01 Kobiolabs, Inc. Kit for predicting or diagnosing nonalcoholic fatty liver disease, and method for diagnosing nonalcoholic fatty liver disease
JP7303372B2 (ja) * 2019-07-30 2023-07-04 コバイオラブス,インコーポレーテッド 肝損傷予防、改善、または治療用組成物、および肝損傷予防、改善、または治療方法
CN114929214A (zh) * 2019-11-22 2022-08-19 阿沃林特有限公司 Sglt2抑制剂治疗原发性胆汁性胆管炎的用途
CN116942684A (zh) * 2020-02-20 2023-10-27 甘莱制药有限公司 一种用于治疗脂肪性肝炎的药物组合物及其制备方法
US11478533B2 (en) * 2020-04-27 2022-10-25 Novo Nordisk A/S Semaglutide for use in medicine
WO2022075756A1 (ko) * 2020-10-08 2022-04-14 주식회사 큐롬바이오사이언스 베타-라파촌을 유효성분으로 포함하는 담즙 정체성 간질환 예방 또는 치료용 약학 조성물
CN120899882A (zh) * 2025-06-16 2025-11-07 中国疾病预防控制中心寄生虫病预防控制所(国家热带病研究中心) Klb蛋白在制备治疗血吸虫感染的药物上的应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR049386A1 (es) * 2004-05-26 2006-07-26 Janssen Pharmaceutica Nv Mercaptoimidazoles como antagonistas del receptor ccr2
ES2440965T3 (es) 2005-01-14 2014-01-31 Chemocentryx, Inc. Heteroaril-sulfonamidas y CCR2
US7622583B2 (en) 2005-01-14 2009-11-24 Chemocentryx, Inc. Heteroaryl sulfonamides and CCR2
WO2007053498A1 (en) * 2005-11-01 2007-05-10 Millennium Pharmaceuticals, Inc. Compounds useful as antagonists of ccr2
US20070219245A1 (en) 2006-03-14 2007-09-20 Cuifen Hou Method of use for substituted dipiperidine ccr2 antagonists
US7683176B2 (en) * 2006-07-14 2010-03-23 Chemocentryx, Inc. Triazolyl pyridyl benzenesulfonamides
US8519135B2 (en) * 2006-07-14 2013-08-27 Chemocentryx, Inc. Heteroaryl sulfonamides and CCR2/CCR9
US7776877B2 (en) * 2007-06-22 2010-08-17 Chemocentryx, Inc. N-(2-(hetaryl)aryl) arylsulfonamides and N-(2-(hetaryl) hetaryl arylsulfonamides
PL2175859T3 (pl) * 2007-07-12 2012-09-28 Chemocentryx Inc Skondensowane heteroarylopirydylo- i fenylo-benzenosulfonamidy jako modulatory CCR2 do leczenia zapalenia
PE20100156A1 (es) * 2008-06-03 2010-02-23 Boehringer Ingelheim Int Tratamiento de nafld
JP5685535B2 (ja) 2008-08-18 2015-03-18 ファイザー インコーポレイティッド Ccr2に対する抗体
ES2674275T3 (es) 2009-12-17 2018-06-28 Centrexion Therapeutics Corporation Antagonistas del receptor CCR2 y usos de los mismos
CN103391931A (zh) * 2011-02-25 2013-11-13 辉瑞有限公司 治疗肝纤维化的方法
ES2869884T3 (es) * 2011-09-16 2021-10-26 Galectin Therapeutics Inc Composiciones de galacto-ramnogalacturonato para el tratamiento de la esteatohepatitis no alcohólica y la enfermedad de hígado graso no alcohólico
AU2013258109A1 (en) * 2012-05-09 2014-10-30 Boehringer Ingelheim International Gmbh Pharmaceutical combinations for the treatment of metabolic disorders
TWI696462B (zh) * 2013-07-10 2020-06-21 日商興和股份有限公司 非酒精性脂肪性肝疾病治療劑
BR112017004708A2 (pt) * 2014-09-12 2017-12-05 Tobira Therapeutics Inc terapia de combinação de cenicriviroc para o tratamento de fibrose
SG11201810602YA (en) * 2016-06-03 2018-12-28 Chemocentryx Inc Method of treating liver fibrosis

Also Published As

Publication number Publication date
CN115154467B (zh) 2024-08-23
RU2740902C2 (ru) 2021-01-21
RU2018145459A (ru) 2020-07-09
JP7431931B2 (ja) 2024-02-15
RU2018145459A3 (https=) 2020-07-09
US20170348293A1 (en) 2017-12-07
EP3463350B1 (en) 2023-09-13
EP3463350A1 (en) 2019-04-10
EP3463350A4 (en) 2020-01-29
AU2017274521B2 (en) 2021-08-19
US20200268727A1 (en) 2020-08-27
US11357760B2 (en) 2022-06-14
IL263245A (en) 2018-12-31
CA3025671A1 (en) 2017-12-07
ES2966111T3 (es) 2024-04-18
SG10202012080UA (en) 2021-01-28
AU2017274521A1 (en) 2018-12-13
JP2019517523A (ja) 2019-06-24
CA3025671C (en) 2024-10-01
WO2017210526A1 (en) 2017-12-07
JP2023022227A (ja) 2023-02-14
CN109475537A (zh) 2019-03-15
BR112018074452A2 (pt) 2019-03-19
ZA201807992B (en) 2023-10-25
MX2018014743A (es) 2019-04-11
US20220313668A1 (en) 2022-10-06
CN115154467A (zh) 2022-10-11
NZ748675A (en) 2024-12-20
MX387070B (es) 2025-03-04
KR102444366B1 (ko) 2022-09-19
KR20190026687A (ko) 2019-03-13
SG11201810602YA (en) 2018-12-28
US10682344B2 (en) 2020-06-16

Similar Documents

Publication Publication Date Title
IL263245B (en) A method for treating liver cirrhosis
ZA201803727B (en) Treatment of fibrosis
IL260539B (en) A method for treating glomerulopathy c3
IL259992A (en) A method for treating increased sensitivity to pain
IL267199A (en) A method for treating epilepsy
EP3484515A4 (en) METHOD FOR TREATING FIBROSE
IL259485A (en) Method of removing tattoos
IL256207B (en) Methods for treating multiple sclerosis
ZA201705997B (en) Method of preventing or treating hearing loss
ZA201804380B (en) Compositions comprising 15-hepe and methods of treating or preventing fibrosis using same
IL253617A0 (en) Snekribirock for the treatment of leprosy
GB201904142D0 (en) Improved method of FT-IMS
EP3491129A4 (en) METHODS OF TREATING OSMIDROSIS
EP3226864A4 (en) Methods of treating fibrosis
EP3091972A4 (en) Method of treating liver disorders
GB2554032B (en) Method of Coating
PL3290175T3 (pl) Sposób przetwarzania powierzchni materiałów drewnopochodnych
GB201602802D0 (en) Method of treatment
EP3148523A4 (en) Method of inhibiting or treating fibrosis
PL3265732T3 (pl) Sposób suszenia budowli
EP3139912A4 (en) Method of treating idiopathic pulmonary fibrosis
SG11201710199PA (en) Methods of treating multiple sclerosis
HK40003258A (en) Method of treating liver fibrosis
HK40000232A (en) Method of treating atherosclerosis
HK40002982A (en) Method of treating or preventing liver conditions